碳水化合物抗原125与达格列净在心力衰竭患者中疗效的关联
本研究基于DAPA-HF试验,分析基线CA125及其变化与射血分数降低心衰患者结局的关系。在3123例有数据患者中,基线CA125中位数13.04 U/mL;CA125>35 U/mL者主要结局风险更高(校正HR 1.59,95%CI 1.29-1.96)。达格列净降低主要结局风险不受基线CA125影响(交互P=0.13和0.75)。
要点
- 基线CA125>35 U/mL是心衰恶化或心血管死亡的独立预测因子。
- 达格列净获益与基线CA125水平无关,各四分位间一致。
- 达格列净组12个月CA125相对变化为-5.2%(95%CI -10.6%至0.5%,P=0.07)。
核心结论
- 在DAPA-HF试验中,升高的CA125是心衰恶化或心血管死亡风险的独立预测因子。
- 达格列净降低心衰恶化或心血管死亡风险的作用不受基线CA125水平影响。
研究设计与样本
- DAPA-HF试验(NCT03036124)的事后分析,纳入射血分数降低的心衰患者。
- 4774例患者中3123例有基线CA125数据,基线及随机后12个月测量CA125。
- 主要结局为首次心衰恶化事件或心血管死亡的复合终点。
主要发现
- 基线CA125中位数13.04 U/mL(IQR 8.78-21.13 U/mL)。
- 与CA125≤35 U/mL相比,CA125>35 U/mL者主要结局校正HR 1.59(95%CI 1.29-1.96)。
- 以Q1(≤8.78 U/mL)为参照,Q2(8.79-13.04 U/mL)HR 0.94(95%CI 0.71-1.24),Q3(13.05-21.13 U/mL)HR 1.22(95%CI 0.94-1.59),Q4(≥21.14 U/mL)HR 1.63(95%CI 1.28-2.09)。
- 达格列净对主要结局的获益在CA125四分位(交互P=0.13)或连续变量(交互P=0.75)分析中一致。
- 12个月时安慰剂校正的CA125相对变化为-5.2%(95%CI -10.6%至0.5%,P=0.07)。
临床怎么用
- 基线CA125>35 U/mL可识别心衰恶化或心血管死亡风险较高的慢性心衰患者。
- 无论基线CA125水平如何,达格列净均可降低心衰恶化或心血管死亡风险。
局限性
- CA125数据仅来自3123/4774例患者,可能存在选择偏倚。
- CA125与达格列净疗效的关联为事后分析,需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elevated circulating carbohydrate antigen 125 (CA125) is a marker of congestion and a predictor of outcomes in acute heart failure (HF). Less is known about CA125 in chronic ambulatory HF with reduced ejection fraction. OBJECTIVES: This study examined the association between baseline CA125 (and changes in CA125) and outcomes in patients with HF with reduced ejection fraction in the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; NCT03036124) trial and its relationship with the effect of dapagliflozin. METHODS: The primary outcome was a composite of a first episode of worsening HF or cardiovascular death. CA125 was measured at baseline and 12 months following randomization. RESULTS: Median baseline CA125 was 13.04 U/mL (IQR: 8.78-21.13 U/mL) in 3,123 of 4,774 patients with available data. Compared with CA125 ≤35 U/mL (upper limit of normal), patients with CA125 >35 U/mL were at a higher risk of the primary outcome (adjusted HR: 1.59; 95% CI: 1.29-1.96). The adjusted risks of the primary outcome relative to quartile 1 (Q1) (≤8.78 U/mL) were as follow: Q2, 8.79-13.04 U/mL (HR: 0.94; 95% CI: 0.71-1.24); Q3, 13.05-21.13 U/mL (HR: 1.22; 95% CI: 0.94-1.59); Q4, ≥21.14 U/mL (HR: 1.63; 95% CI: 1.28-2.09). The beneficial effect of dapagliflozin compared with placebo on the primary outcome was consistent whether CA125 was analyzed in quartiles (interaction P = 0.13) or as a continuous variable (interaction P = 0.75). The placebo-corrected relative change in CA125 at 12 months was -5.2% (95% CI: -10.6% to 0.5%; P = 0.07). CONCLUSIONS: In DAPA-HF, elevated CA125 levels were an independent predictor of the risk of worsening HF or cardiovascular death. Dapagliflozin reduced the risk of worsening HF or cardiovascular death regardless of baseline CA125.
引用
- Docherty, McDowell, Welsh, et al. Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure. J Am Coll Cardiol. 2023. PMID: 37407113. doi:10.1016/j.jacc.2023.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。